Clinical trials: Glaucoma, Primary
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Glaucoma
Primary Tube Versus Trabeculectomy Study
The purpose of the Primary Tube Versus Trabeculectomy (PTVT) Study is to compare the long-term safety and efficacy of nonvalved tube shunt surgery to trabeculectomy with mitomycin C in eyes that have not had previous ocular…
- Trial name
- NCT00666237
- Testing
- Tube shunt surgery, Trabeculectomy, Mitomycin C
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 242 people
- Sponsor
- University of Miami
Open-Angle Glaucoma
Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.
- Trial name
- NCT02928289
- Testing
- VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma and Ocular Hypertension
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02371746
- Testing
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Envisia Therapeutics
Primary Open Angle Glaucoma, Ocular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- ANGEL-2 (NCT04742283)
- Testing
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- 41 sites in United States
- Volunteers
- 323 people
- Sponsor
- Santen Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01628588
- Testing
- bimatoprost 0.01%
- Where
- Netherlands
- Volunteers
- 854 people
- Sponsor
- Allergan
Primary Angle-Closure Glaucoma, Primary Angle Closure Without Glaucoma Damage
Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent
Assessing the safety and efficacy of a micro-bypass stent in combination with cataract surgery in subjects with primary angle closure.
- Trial name
- NCT03647033
- Testing
- iStent implantation
- Where
- Singapore
- Volunteers
- 32 people
- Sponsor
- Khoo Teck Puat Hospital
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma
POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma
This is an open-label, randomized, multi-center, active-controlled parallel-comparison of POLAT-001 to latanoprost ophthalmic solution in patients with ocular hypertension and primary open-angle glaucoma.
- Trial name
- NCT02466399
- Testing
- POLAT-001, Latanoprost ophthalmic solution
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Peregrine Ophthalmic
Primary Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
- Trial name
- NCT01915940
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- ForSight Vision5, Inc.
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used…
- Trial name
- NCT01342081
- Testing
- DE-111 ophthalmic solution, Tafluprost ophthalmic solution 0.0015%, Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 489 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in…
- Trial name
- NCT01215786
- Testing
- timolol ophthalmic solution 0.5%
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Allergan
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Primary Open Angle Glaucoma
Post Market Study of the InnFocus MicroShunt
Prospective, multicentric, single arm post market study to gather safety and effectiveness data on the CE Marked InnFocus MicroShunt (MIDI Arrow) device in primary open angle glaucoma patients
- Trial name
- NCT02177123
- Testing
- InnFocus MicroShunt implantation
- Where
- 6 sites in France, Netherlands and 2 more
- Volunteers
- 107 people
- Sponsor
- InnFocus Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the efficacy and tolerance of generic travoprost with its brand name formulation. In this open label, randomized, crossover study, the primary outcome will be intraocular pressure and the…
- Trial name
- NCT02796560
- Testing
- Brand name travoprost, Generic travoprost
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Université de Sherbrooke
Glaucoma
Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
The study aims to further understand glaucoma pathogenesis and progression by utilizing enhanced depth imaging optical coherence tomography to visualize and measure lamina cribrosa in vivo and segmentation technology to…
- Trial name
- NCT02622191
- Testing
- Spectral domain Optical Coherence Tomography
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Wills Eye
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04024072
- Testing
- Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Padagis LLC
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan